Incruse

(umeclidinium)
Incruse Ellipta 62.5 MCG/INHAL Dry Powder Inhaler, 30 BlistersIncruse Ellipta 62.5 MCG/INHAL Dry Powder Inhaler, 7 Blisters
NO BOXED WARNING

Dosage & administration

drug label

Incruse prescribing information

prior authorization

Incruse prior authorization resources

Most recent Incruse prior authorization forms

View By Payer
Verified: Feb 07, 2024Kaiser Foundation Health Plan - Chronic High-Dose Opioid Therapy Prior Authorization Form Washington
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Medical Injectable Specialty Drug Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Outpatient Chemotherapy Prior Authorization Form (Medical Benefit)
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Specialty Drug Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Non-Formulary Drug Coverage Prior Authorization Form

Most recent state uniform prior authorization forms

Verified: Jan 28, 2024Oregon - Uniform Prior Authorization Form
Verified: Jan 28, 2024Colorado - Uniform Prior Authorization Form
Verified: Jan 28, 2024Michigan - Uniform Prior Authorization Form
Verified: Jan 28, 2024Hawaii - Uniform Prior Authorization Form
Verified: Jan 28, 2024Minnesota - Uniform Prior Authorization Form
Verified: Jan 28, 2024New Hampshire - Uniform Prior Authorization Form
Verified: Jan 28, 2024New Mexico - Uniform Prior Authorization Form
Verified: Jan 28, 2024Texas - Uniform Prior Authorization Form
Verified: Jan 28, 2024Louisiana - Uniform Prior Authorization Form
Verified: Jan 28, 2024Arizona - Uniform Prior Authorization Form
Verified: Jan 28, 2024Indiana - Uniform Prior Authorization Form
Verified: Jan 28, 2024Illinois - Uniform Prior Authorization Form
Learn More

Benefits investigation

Patient Authorization Form - GSKForYou
Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information
Learn More

financial assistance

Incruse financial assistance options

Foundation programs

under insured
no insurance
goverment insurance
65+
GSK For You: GSK Patient Assistance
Learn More

PubMed™ | Incruse

Incruse PubMed™ News

patient education

Incruse patient education

To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link

Patient toolkit

About Incruse Ellipta
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Incruse FAQs

8.1 Pregnancy Risk SummaryInsufficient data are available on the use of umeclidinium in pregnant women to determine a drug-associated risk. Animal studies with pregnant rats and rabbits, exposed to umeclidinium through inhalation or subcutaneous routes, showed no adverse effects on embryofetal development at exposures approximately 50 and 200 times, respectively, the human exposure at the maximum recommended daily inhaled dose (MRHDID).
8.2 Lactation Risk SummaryThere is no information regarding the presence of umeclidinium in human milk, its effects on breastfed infants, or its impact on milk production. Umeclidinium was detected in the plasma of offspring from lactating rats treated with umeclidinium, suggesting its presence in maternal milk. The decision to breastfeed should consider the benefits of breastfeeding along with the clinical need for INCRUSE ELLIPTA, weighing potential effects on the breastfed child from umeclidinium or the maternal condition.
8.4 Pediatric UseINCRUSE ELLIPTA is not approved for use in children, and its safety and efficacy in pediatric patients have not been established.
8.5 Geriatric UseAvailable data do not suggest the need for dosage adjustment of INCRUSE ELLIPTA in geriatric patients. However, some older individuals may exhibit greater sensitivity, although no overall differences in safety or effectiveness were observed in clinical trials between elderly and younger subjects.
8.6 Hepatic ImpairmentPatients with moderate hepatic impairment (Child-Pugh score of 7-9) did not show relevant increases in Cmax or AUC, and protein binding did not differ from healthy controls. Studies in subjects with severe hepatic impairment have not been conducted.
8.7 Renal ImpairmentPatients with severe renal impairment (CrCl <30 mL/min) did not exhibit relevant increases in Cmax or AUC, and protein binding did not differ from healthy controls. No dosage adjustment is required for patients with renal impairment.
FAQ Data Source